Dr. KinyasHair Clinic · IstanbulLibrary ←
Science and Research Centre / Hair Loss and Treatments

Dr. Kinyas Hair Clinic · Science and Research Centre

Hair Exosomes: Promising Research Needs Product-Specific Evidence

Exosome can label products with different origins and preparation. Positive hair-study findings require knowing which product, patients and comparator were studied before asking whether exosomes work.

Extracellular vesicles are not stem cells

Extracellular vesicles participate in cell communication and differ from living stem-cell treatment. An exosome label alone defines neither source, purity, contents nor efficacy. Manufacturing and characterisation differences can produce different outcomes. [1]

Follicular signalling and cell interactions justify research. Culture or animal effects do not prove new permanent human hair. Mechanism and patient outcomes require separate translational steps. [1]

What does a small randomised pilot show?

Amini’s 2025 study compared a specific botanical exosome-containing formula with placebo. The abstract reports favourable short-term count changes in 20 male participants. This is a limited clinical signal. [2]

Botanical components were not tested separately, so effects cannot be attributed solely to vesicles. Findings cannot transfer to every cord-derived or other tissue product. Small size and short follow-up cannot establish personal response or long-term safety. [2]

A protocol is not a result

Tian’s 2026 protocol plans 59 participants to study small vesicles from umbilical-cord mesenchymal cells. It records a research question and design, not successful treatment results. [3]

Randomised controlled in a title is insufficient: check whether the article is a protocol or results. Planned numbers are not analysed numbers. Positive expectations cannot become present-day guarantees.

Assessing new product studies

Review concomitant actives as well as source. Needling, drugs or other components may mean a whole package was tested. Isolating one contribution requires an appropriate control. [1], [2]

Counts, diameter, growth-phase proportion and satisfaction differ. Change in one does not mean equal new growth throughout the scalp. Photography, follow-up length and post-treatment persistence also matter.

Does registration or a laboratory certificate equal approval?

Research registration is not marketing approval. FDA information emphasises this distinction; current Turkish product status requires separate verification. [4]

Quality and sterility certificates do not equal disease-specific efficacy trials. Ask whether a cited study matches the product, route and patients offered. Another preparation’s article alone is insufficient bridging evidence. [1]

How should it inform your transplant decision?

An AGA study does not establish graft survival benefits or solve limited reserves. Such claims require direct research. This review establishes no shared graft-survival evidence for all products. [1], [2]

Discuss diagnosis, goals, alternatives and uncertainty with Dr. Kinyas if a product is proposed. Research progress does not make it a compulsory package. This article verifies neither use nor approval of a particular clinic product.

References and access limitations

This article is based on a targeted review of sources; it is not an original systematic review.

  1. Bellani D et al. Pathophysiological mechanisms of hair follicle regeneration and potential therapeutic strategies. Stem Cell Res Ther. DOI: 10.1186/s13287-025-04420-4.

    Mechanistic/translational review. Culture/animal findings not presented as product efficacy; illustrations not copied.

  2. Amini F et al. A Pilot RCT Evaluating the Efficacy of an Exosome-Containing Plant Extract Formulation for Treating Male Alopecia. Life. 2025;15:500. DOI: 10.3390/life15030500.

    Small randomised pilot; abstract and prior access record. Abstract reports 20 analysed; previous body record began with 24, a different denominator. Full product characterisation and conflicts of interest were not independently assessed. Component effects not separately tested.

  3. Tian R et al. A Randomized Controlled Clinical Trial Protocol of Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles… FASEB J. 2026;40:e71496. DOI: 10.1096/fj.202504430.

    Study protocol; indexed abstract. 59 planned, not results. Assessment based on the published protocol abstract.

  4. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies. 3 June 2021.

    Regulatory patient information; official page accessed. General risks are not product-specific scalp incidence. Not Turkish law or a complete current approval list.

← Back to section
WhatsApp
DR. KINYAS HAIR CLINIC

Quick Contact

Leave your details and we will contact you through your preferred channel.

How should we contact you?

Dr. Kinyas Hair Clinic uses your details to respond to your request and contact you.